Patents by Inventor Christopher Ton
Christopher Ton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150729Abstract: The instant invention discloses a closed-system, serum-free, microcarrier-based up-stream process to produce dengue virus. The process comprises a closed-system cell expansion comprising cell passages taking place in closed-system containers. These cell expansions represent a closed process, with replacement media, a cell-detachment agent, and quench medium added though sterile, weldable tubing (a closed-system environment) to eliminate all open aseptic processing following the initial vial thaw of the adherent cells. The viral production takes place in a closed-system bioreactor in adherent cell culture grown on microcarriers providing sufficient cell mass to support the production of dengue virus.Type: ApplicationFiled: March 17, 2022Publication date: May 9, 2024Applicant: Merck Sharp & Dohme LLCInventors: Pooja Chadha, Kent Harley Hamaker, Shannon Haughney, Samantha J. Marrone, Christopher Ton, Igor Zabrodin
-
Publication number: 20240117315Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: ApplicationFiled: June 8, 2023Publication date: April 11, 2024Inventors: Samson TOM, Christopher TON, Alla DANILKOVITCH
-
Patent number: 11708560Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: GrantFiled: December 23, 2019Date of Patent: July 25, 2023Assignee: Mesoblast International SarlInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20230089901Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.Type: ApplicationFiled: September 23, 2022Publication date: March 23, 2023Inventors: Alla DANILKOVICH, Robert E. NEWMAN, Samson TOM, Christopher TON, Zhanling WANG, Randell G. YOUNG
-
Publication number: 20200231936Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: ApplicationFiled: December 23, 2019Publication date: July 23, 2020Applicant: Mesoblast International SarlInventors: Samson TOM, Christopher Ton, Alla Danilkovitch
-
Publication number: 20200197444Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.Type: ApplicationFiled: November 25, 2019Publication date: June 25, 2020Inventors: Alla Danilkovich, Robert E. Newman, Samson Tom, Christopher Ton, Zhanling Wang, Randell Young
-
Patent number: 10550369Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: GrantFiled: April 4, 2018Date of Patent: February 4, 2020Assignee: Mesoblast International SarlInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20180291347Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: ApplicationFiled: April 4, 2018Publication date: October 11, 2018Applicant: Mesoblast International SarlInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Patent number: 9963678Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: GrantFiled: March 19, 2015Date of Patent: May 8, 2018Assignee: Mesoblast International SàrlInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20180008642Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.Type: ApplicationFiled: May 23, 2017Publication date: January 11, 2018Inventors: Alla Danilkovich, Robert E. Newman, JR., Samson Tom, Christopher Ton, Zhanling Wang, Randell G. Young
-
Patent number: 9828586Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: GrantFiled: December 23, 2013Date of Patent: November 28, 2017Assignee: MESOBLAST INTERNATIONAL SÁRLInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20150247122Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: ApplicationFiled: March 19, 2015Publication date: September 3, 2015Inventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20140112893Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: ApplicationFiled: December 23, 2013Publication date: April 24, 2014Applicant: Mesoblast International SarlInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20140105872Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.Type: ApplicationFiled: December 16, 2013Publication date: April 17, 2014Inventors: Alla Danilkovich, Robert E. Newman, JR., Samson Tom, Christopher Ton, Zhanling Wang, Randell G. Young
-
Patent number: 8637004Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.Type: GrantFiled: August 14, 2009Date of Patent: January 28, 2014Assignee: Mesoblast International SarlInventors: Alla Danilkovich, Robert E. Newman, Jr., Samson Tom, Christopher Ton, Zhanling Wang, Randell G. Young
-
Publication number: 20120087933Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: ApplicationFiled: October 6, 2011Publication date: April 12, 2012Inventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20100068191Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.Type: ApplicationFiled: August 14, 2009Publication date: March 18, 2010Inventors: Alla Danilkovich, Robert E. Newman, JR., Samson Tom, Christopher Ton, Zhanling Wang, Randell G. Young